|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:brand
|
gptkb:Toujeo_Solo_Star
|
|
gptkbp:clinical_trial
|
Phase 3
blood sugar control
basal insulin therapy
|
|
gptkbp:contraindication
|
hypersensitivity to insulin glargine
severe hypoglycemia
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:education
|
storage instructions
proper injection technique
recognize hypoglycemia symptoms
monitor blood glucose
dosing schedule
|
|
gptkbp:effective_date
|
gptkb:2015
|
|
gptkbp:form
|
injection
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Toujeo
|
|
gptkbp:indication
|
long-acting insulin therapy
|
|
gptkbp:ingredients
|
gptkb:insulin_glargine
|
|
gptkbp:interacts_with
|
corticosteroids
beta-blockers
thiazolidinediones
|
|
gptkbp:is_available_on
|
generic
|
|
gptkbp:is_used_for
|
gptkb:Company
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:packaging
|
pre-filled pen
|
|
gptkbp:pharmacokinetics
|
steady-state concentration
long-acting insulin effect
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:provides_information_on
|
ADA Standards of Medical Care
EASD Guidelines
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:related_to
|
gptkb:Company
gptkb:Lantus
|
|
gptkbp:research
|
patient adherence
impact on quality of life
long-term safety
comparison with other insulins
insulin therapy effectiveness
|
|
gptkbp:safety_features
|
well-tolerated
|
|
gptkbp:side_effect
|
weight gain
injection site reactions
hypoglycemia
|
|
gptkbp:website
|
upper arm
thigh
abdomen
|
|
gptkbp:bfsParent
|
gptkb:Sanofi_Aventis
gptkb:Basaglar
gptkb:Lantus
gptkb:Humulin
|
|
gptkbp:bfsLayer
|
4
|